Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy

OBJECTIVE: Subcutaneous (SC) application of bortezomib has been recently introduced as a new application route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes of bortezomib-based therapy in multiple myeloma (MM) patients treated using either intravenous (IV) or su...

Descripción completa

Detalles Bibliográficos
Autores principales: Minarik, Jiri, Pavlicek, Petr, Pour, Ludek, Pika, Tomas, Maisnar, Vladimir, Spicka, Ivan, Jarkovsky, Jiri, Krejci, Marta, Bacovsky, Jaroslav, Radocha, Jakub, Straub, Jan, Kessler, Petr, Wrobel, Marek, Walterova, Lenka, Sykora, Michal, Obernauerova, Jarmila, Brozova, Lucie, Gregora, Evzen, Adamova, Dagmar, Gumulec, Jaromir, Adam, Zdenek, Scudla, Vlastimil, Hajek, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396992/
https://www.ncbi.nlm.nih.gov/pubmed/25875484
http://dx.doi.org/10.1371/journal.pone.0123866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396992/
https://www.ncbi.nlm.nih.gov/pubmed/25875484
http://dx.doi.org/10.1371/journal.pone.0123866

Ejemplares similares